You are here

Shire

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

5 Pharma & Biotech Stocks That Could Be Big Winners in Q2 Earnings

Yahoo/Zacks.com

Gilead Sciences

Flag link:

Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab

Shire blasts rival Roche for its “misleading” case for hemophilia trailblazer emicizumab

Motley Fool

Flag link:

Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul

Rare-Disease Drugmakers Join in Worries Over GOP Health Overhaul

Bloomberg

healthcare reform

Jazz Pharmaceuticals

Vertex Pharmaceuticals

Flag link:

Shire will cut U.S. locations and move HQ in consolidation push

Shire will cut U.S. locations and move HQ in consolidation push

Fierce Biotech

Flag link:

Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge

Shire’s Ornskov dictates another big revamp, with R&D/HQ moving into Cambridge

Endpoints

Flemming Ornskov

Flag link:

Pfizer Fueling Growth Of Competitors' Pipelines

Pfizer Fueling Growth Of Competitors' Pipelines

Forbes

Clovis Oncology

Puma Biotechnology

Flag link:

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

FDA OKs CSL’s new HAE drug, already embroiled in a blockbuster fight with Shire

Endpoints

hereditary angiodema

Flag link:

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

A decade behind schedule, Shire finally gets an FDA OK for long-acting ADHD drug

Endpoints

Flag link:

Kamada slumps after Shire hands back rights

Kamada slumps after Shire hands back rights

BioPharma Dive

alpha-1 antitrypsin

graft vs host disease

Flag link:

Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643

Shire Is Poised To Dominate The HAE Market After Strong Phase III Data For SHP643

Seeking Alpha

Flag link:

Shire writes off a shot at long-acting hemophilia drug after small study flops

Shire writes off a shot at long-acting hemophilia drug after small study flops

Endpoints

Xenetic Biosciences

clinical trials

Flag link:

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

Shire’s multibillion-dollar gamble on lanadelumab pays off with stellar PhIII data, quick marketing application

Endpoints

Flag link:

Shire commits up to $535M for Parion's dry eye drug

Shire commits up to $535M for Parion's dry eye drug

BioPharma Dive

dry eye disease

Flag link:

Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch

Shire, armed with new rare disease patent, aims to block CSL's Haegarda launch

Fierce Pharma

hereditary angiodema

Flag link:

Shire's DTC move to scrap smiling patients for double 'i's pays off—and it thinks other pharmas should take note

Shire's DTC move to scrap smiling patients for double 'i's pays off—and it thinks other pharmas should take note

Fierce Pharma

dry eye disease

Flag link:

About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet

About that pharma M&A comeback? Sorry. 2017's not bringing it—at least not yet

Fierce Pharma

Ariad Pharmaceuticals

Flag link:

Shire Rises on Encouraging Angioedema Results

Shire Rises on Encouraging Angioedema Results

TheStreet.com

Flag link:

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

2016 went out like a lamb in the biopharma M&A world. Will it roar back in 2017? Plus, top 10 deals

Endpoints

Flag link:

Baxalta pushes Shire to record revenues

Baxalta pushes Shire to record revenues

BioPharma Dive

Flag link:

Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug

Shire finally finishes a 10-year trek back to the FDA with an old ADHD drug

Endpoints

Flag link: